Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263363 · ClinicalTrials.gov registry record · Phase 4
Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 12,248
- Enrollment target
NCT04263363 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 12,248 participants.
The verdict
NCT04263363, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12,248 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.
Interventions
- DRUG Sugammadex 100 MG/ML [Bridion]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,248 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04263363
The ClinicalTrials.gov registry entry for NCT04263363 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12,248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sugammadex 100 MG/ML [Bridion] is the first listed.
NCT04263363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04263363 about?
NCT04263363 is a clinical study titled "Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications". The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and i...
What is the current status of trial NCT04263363?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12,248 participants. The study started on 2022-02-18. Estimated completion is 2025-05-07.
What interventions are being tested in trial NCT04263363?
The interventions under investigation include: Sugammadex 100 MG/ML [Bridion] (DRUG).
Who is sponsoring clinical trial NCT04263363?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.